Reference
Medsafe. PHARMACOVIGILANCE ISSUES - Consideration of bufexamac medicines under section 36 of the Medicines Act 1981 Internet Document : 19 Jul 2021. Available from: URL: https://www.medsafe.govt.nz/profs/adverse/Minutes186.htm
Rights and permissions
About this article
Cite this article
Bufexamac products require reclassification; unfavourable risk-benefit. Reactions Weekly 1866, 1 (2021). https://doi.org/10.1007/s40278-021-99697-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-99697-3